[1] Drug costs and bacterial susceptibility after implementing a single-fluoroquinolone use policy at a university hospital

[2] Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men

[3] Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis

[4] Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity

[5] Fidaxomicin versus vancomycin for Clostridium difficile infection